Fertility and breast cancer
Journal Title: OncoReview - Year 2016, Vol 6, Issue 4
Abstract
Breast cancer is the most common cancer among females worldwide. The mean age of breast cancer patients is > 60 yrs old, and it is seldom found in women < 40 yrs old (6.5%) and in very young women < 35 yrs old (0.6%). In young females, fertility and all its aspects are an additional therapeutic challenge. Before initiating treatment, the oncologist should offer effective contraception to be applied throughout the therapy, bearing in mind that fertility preservation is of utmost importance. When it comes to breast cancer in pregnancy, the attending physician should use a therapy which is safe for both the mother and the foetus.
Authors and Affiliations
Joanna Kufel-Grabowska
Keywords
Related Articles
- EP ID EP186903
- DOI 10.5604/01.3001.0009.5057
- Views 213
- Downloads 0
The quality of life and the sexual activity of prostate cancer patients after radical radiotherapy in comparison with group without cancer
[b]Background:[/b] Prostate cancer is a disease with a significant impact on quality of life (QoL) both during and after cancer treatment.[b]The aim of study[/b]: The aim of this study was assessment of QoL and sexual ac...
Nasopharyngeal carcinoma – treatment possibilities in patients with primary metastatic carcinoma
This article presents methods of effective treatment of primary metastatic nasopharyngeal carcinoma, both causative and symptomatic, taking into account possible available treatment therapies (chemotherapy, targeted ther...
Papillary renal cell carcinoma – case report of a patient with disseminated disease treated with pazopanib with several years of survival against reviewing current literature
Papillary renal cell carcinoma is the second most common histological type of renal cell carcinoma with distinct cytogenetics, histology and prognosis. It exhibits significantly poorer response to molecular targeted ther...
Radiotherapy in patients with cardiac implantable electronic devices – clinical experience
The number of patients with cardiac implantable electronic devices (CIEDs) constantly increases and due to growing incidence of cancer, many of them will require an anticancer treatment. At least a half of patients treat...
Tyrosine kinase inhibitors – should we worry about cardiovascular complications?
Small-molecular tyrosine kinase inhibitors constitute an effective therapeutic option in patients with hematologic malignancies and solid tumours. On the other hand, the significance of cardiovascular adverse events asso...